Agefi – Dow Jones |
Sanofi: FDA grants priority review to treatment for hemophilia A | Photo credits: Sanofi Pasteur/Vincent Moncorgé
PARIS (Agefi-Dow Jones)–The pharmaceutical company Sanofi announced on Tuesday that the American health authority, the Food and Drug Administration (FDA), had granted priority review procedure to its treatment efanesoctocog alpha for the treatment of hemophilia A.
This priority review concerns data from a phase III study. The decision on a possible commercialization on the American treatment market should take place on February 28, 2023, Sanofi said in a press release.
-Francois Schott, Agefi-Dow Jones; +33 (0)1 41 27 47 92; [email protected] ed: VLV
Agefi-Dow Jones The financial newswire
Dow Jones Newswires
August 30, 2022 01:53 ET (05:53 GMT)